The FDA's finalization of rules to regulate lab-developed tests in a manner similar to other diagnostics is likely to have a positive impact on Quest Diagnostics. This regulatory change could streamline operations, potentially reduce compliance costs, and enhance the company's product offerings' marketability. As a result, investor sentiment is likely to be positive, driving up the stock price in the short term.